000148590 001__ 148590
000148590 005__ 20250120165542.0
000148590 0247_ $$2doi$$a10.1021/acs.molpharmaceut.7b00295
000148590 0248_ $$2sideral$$a135598
000148590 037__ $$aART-2017-135598
000148590 041__ $$aeng
000148590 100__ $$aCañibano-Hernández, Alberto
000148590 245__ $$aAlginate Microcapsules Incorporating Hyaluronic Acid Recreate Closer <i>in Vivo</i> Environment for Mesenchymal Stem Cells
000148590 260__ $$c2017
000148590 5060_ $$aAccess copy available to the general public$$fUnrestricted
000148590 5203_ $$aThe potential clinical application of alginate cell microencapsulation has advanced enormously during the past decade. However, the 3D environment created by alginate beads does not mimic the natural extracellular matrix surrounding cells in vivo, responsible of cell survival and functionality. As one of the most frequent macromolecules present in the extracellular matrix is hyaluronic acid, we have formed hybrid beads with alginate and hyaluronic acid recreating a closer in vivo cell environment. Our results show that 1% alginate-0.25% hyaluronic acid microcapsules retain 1.5% alginate physicochemical properties. Moreover, mesenchymal stem cells encapsulated in these hybrid beads show enhanced viability therapeutic protein release and mesenchymal stem cells' potential to differentiate into chondrogenic lineage. Although future studies with additional proteins need to be done in order to approach even more the extracellular matrix features, we have shown that hyaluronic acid protects alginate encapsulated mesenchymal stem cells by providing a niche-like environment and remaining them competent as a sustainable drug delivery system.
000148590 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000148590 590__ $$a4.556$$b2017
000148590 591__ $$aPHARMACOLOGY & PHARMACY$$b27 / 260 = 0.104$$c2017$$dQ1$$eT1
000148590 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b24 / 133 = 0.18$$c2017$$dQ1$$eT1
000148590 592__ $$a1.572$$b2017
000148590 593__ $$aDrug Discovery$$c2017$$dQ1
000148590 593__ $$aPharmaceutical Science$$c2017$$dQ1
000148590 593__ $$aMolecular Medicine$$c2017$$dQ1
000148590 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000148590 700__ $$aSaenz del Burgo, Laura
000148590 700__ $$aEspona-Noguera, Albert
000148590 700__ $$aOrive, Gorka
000148590 700__ $$aHernández, Rosa M.
000148590 700__ $$0(orcid)0000-0002-8666-622X$$aCiriza, Jesús
000148590 700__ $$aPedraz, Jose Luis
000148590 773__ $$g14, 7 (2017), 2390-2399$$pMol. pharm.$$tMolecular pharmaceutics$$x1543-8384
000148590 8564_ $$s1246243$$uhttps://zaguan.unizar.es/record/148590/files/texto_completo.pdf$$yPostprint
000148590 8564_ $$s708798$$uhttps://zaguan.unizar.es/record/148590/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000148590 909CO $$ooai:zaguan.unizar.es:148590$$particulos$$pdriver
000148590 951__ $$a2025-01-20-14:53:44
000148590 980__ $$aARTICLE